Merck KGaA has been granted marketing authorization by the European Commission to extend the use of Erbitux in combination with radiotherapy, to treat patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Erbitux will be available in all 25 member states of the EU as well as Iceland and Norway. Erbitux is already licensed in 53 countries for metastatic colorectal cancer after failure of irinotecan-based chemotherapy. The license application is based on the res...